Wedbush upgraded USANA Health Sciences USNA from Underperform to Neutral and maintained a $40.00 price target.
Wedbush noted, "Our earlier concerns over N. America recruiting trends, which remain down single digits in the face of emerging competitor ARIIX (which was formed last year by former senior USANA executives and distributors), have been more than offset in recent quarters by stronger-than-expected sales in Asia, driven by faster-than-expected economic growth across major economies where USANA has successfully penetrated. As a result, we are increasing our 2013 forecasts for revenue to $710 million from $682 million, and for EPS to $5.14 from $4.65."
USANA Health Sciences closed at $37.53 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in